Successful Multidimensional Intervention in a Patient with Intractable Neuropathic Cancer Pain

At this point she was transferred from her community hospital to the palliative care unit. Medications consisted of morphine 1 mg/hour, clonidine 0.4 mg/hour, and bupivacaine 0.075 mg/hour, all administered epidurally; amitriptyline 50 mg orally twice a day, lorazepam 4 mg orally every night, ibuprofen as needed, ketorolac as needed, and oxycodone as needed. On physical examination, the patient was drowsy with a Folstein's Mini-Mental State Examination (2) score of 18/30. There were no masses or tenderness in the buttocks or hips. Although strength testing was normal, the patient was unsteady on her feet and dependent upon a wheelchair for mobility. Urinary catheterization was required. Blood work was unremarkable. Methadone was initiated on Day 0 at a dosage of 10 mg orally every 8 hours and then titrated to achieve pain control. Concurrently the epidural medications, amitriptyline, and lorazepam were tapered and discontinued by Day 9. On Day 5 the patient developed a fever and elevated white blood cell count. Antibiotics were administered and the epidural, central venous, and urinary catheters removed, with the subsequent resolution of infective signs. Transient agitation and hallucinations were treated with haloperidol. As the patient became more alert and less confused, she was able to verbalize her fears related to the illness. It became apparent that her complaints of severe pain reflected major psychological distress. She was also found to have a history of alcoholism, scoring 3/4 on the CAGE questionnaire (3). Supportive counseling was provided by the multidisciplinary team, and rehabilitation became a major focus of her care. Although she did not fully gain insight in the nature of her distress and continued to report CASE REPORT

[1]  E. Bruera,et al.  A prospective multicenter assessment of the Edmonton staging system for cancer pain. , 1995, Journal of pain and symptom management.

[2]  F. Bruera,et al.  New developments in the assessment of pain in cancer patients , 1994, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[3]  E. Bruera,et al.  Methadone in the management of cancer pain: a review , 1993, Pain.

[4]  E. Bruera,et al.  Cognitive failure in patients with terminal cancer: a prospective study. , 1992, Journal of pain and symptom management.

[5]  G. Pasternak,et al.  Individual variability in the response to different opioids: report of five cases , 1992, Pain.

[6]  Eduardo Bruera,et al.  The Edmonton Symptom Assessment System (ESAS): A Simple Method for the Assessment of Palliative Care Patients , 1991, Journal of palliative care.

[7]  M. Ivarsson,et al.  Differences in efficacies between morphine and methadone demonstrated in the guinea pig ileum: a possible explanation for previous observations on incomplete opioid cross-tolerance. , 1989, Pharmacology & toxicology.

[8]  G. Geller,et al.  Prevalence, detection, and treatment of alcoholism in hospitalized patients. , 1989, JAMA.

[9]  J. Ewing,et al.  Detecting alcoholism. The CAGE questionnaire. , 1984, JAMA.

[10]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[11]  E. Bruera,et al.  The Edmonton Functional Assessment Tool: preliminary development and evaluation for use in palliative care. , 1997, Journal of pain and symptom management.